Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellstagecellscancereverolimus
  Phrases that lowered it: masspatients whocd4groupvaccines
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 5.4% (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Sponsor's past trials: 203 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 24 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 20.2% (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 26196 (lowers risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design
• Number of arms: 1 (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports before start: 109635 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports marked serious: 88.0% (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma NCT00869999 · started 2009 · scored riskier than 98% of active trials completed
• Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma NCT00671112 · started 2008 · scored riskier than 59% of active trials terminated
• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy NCT00790036 · started 2009 · scored riskier than 51% of active trials completed
• The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas NCT01567475 · started 2011 · scored riskier than 71% of active trials completed
• Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma NCT02254239 · started 2016 · scored riskier than 67% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.